证券代码：002437 证券简称：誉衡药业 公告编号：2025-054 哈尔滨誉衡药业股份有限公司 哈尔滨誉衡药业股份有限公司（以下简称"公司"）副总经理李润宝先生、 副总经理王小航先生及董事、副总经理、董事会秘书刘月寅女士保证信息披露的 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 润宝先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 小航先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 经理、董事会秘书刘月寅女士计划自本公告披露之日起 15 个交易日后的三个月 内以集中竞价方式减持公司股份 259,619 股（占公司股份总数的 0.0116%）。 公司于 2025 年 5 月 29 日收到副总经理李润宝先生、副总经理王小航先生及 董事、副总经理、董事会秘书刘月寅女士出具的《股份减持计划告知函》。现将 有关情况公告如下： 一、拟减持股 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-054 哈尔滨誉衡药业股份有限公司 关于公司部分董事及高级管理人员减持股份的预披露公告 哈尔滨誉衡药业股份有限公司（以下简称"公司"）副总经理李润宝先生、 副总经理王小航先生及董事、副总经理、董事会秘书刘月寅女士保证信息披露的 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、持有公司股份 2,350,000 股（占公司总股本比例 0.1046%）的副总经理李 润宝先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 2、持有公司股份 2,350,000 股（占公司总股本比例 0.1046%）的副总经理王 小航先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 注：如计划减持期间有送股、资本公积金转增股本、配股等除权除息事项，减持股份数 量将相应进行调 ...

誉衡药业（002437）公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计 划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别 拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减 持原因是个人资金需求，减持价格将按市场价格确定。 ...

医药生物行业资金流出榜 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 300534 | 陇神戎发 | 11.29 | 27.54 | 13261.07 | | 002437 | 誉衡药业 | 9.89 | 9.40 | 12683.64 | | 603259 | 药明康德 | 0.86 | 0.88 | 12103.63 | | 000953 | 河化股份 | 9.99 | 18.71 | 12103.00 | | 000078 | 海王生物 | 9.83 | 2.63 | 7433.92 | | 300558 | 贝达药业 | 7.94 | 4.81 | 7368.93 | | 002422 | 科伦药业 | -0.45 | 1.30 | 6954.77 | | 002907 | 华森制药 | 9.98 | 2.87 | 6810.87 | | 002821 | 凯莱英 | 4.45 | 1.95 | 6219.45 | | 600216 | 浙江医药 | 3.10 | ...

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

Group 1: Market Overview - The People's Bank of China conducted a 7-day reverse repo operation of 448 billion yuan at an interest rate of 1.40% on May 27, with 357 billion yuan of reverse repos maturing on the same day [1][5] - A-shares opened slightly lower but showed signs of recovery, with the Shanghai Composite Index fluctuating and turning positive [5][6] - The consumer sector, particularly food and beverage, showed initial strength, while the pharmaceutical sector rebounded [6][12] Group 2: Pharmaceutical Sector - The pharmaceutical and biotechnology sector experienced a partial rebound, with notable stocks such as Longshen Rongfa hitting the daily limit, and Sanofi Guojian rising over 10% [12][13] - Hong Kong pharmaceutical stocks also saw gains, with notable increases in companies like CSPC Pharmaceutical and China Biologic Products [8][14] Group 3: Nuclear Power Sector - The nuclear power sector continued its recent strong performance, with stocks like Shangwei Co. and Rongfa Nuclear Power achieving multiple consecutive gains [9][11] - Recent reports indicate a positive outlook for the controllable nuclear fusion industry, driven by favorable policies and increased financing [11] Group 4: Food and Beverage Sector - The food and beverage sector saw a surge, with stocks like Kuaijishan and Junyao Health achieving significant gains [15][16] - Kuaijishan's market capitalization surpassed that of Guyue Longshan, establishing it as a leading player in the yellow wine industry [15] Group 5: Cultivated Diamond Sector - The cultivated diamond sector experienced a sharp rise, with stocks like Huanghe Xuanfeng and Huifeng Diamond hitting the daily limit [17][18] - Huanghe Xuanfeng announced a partnership to establish a joint venture focused on advanced semiconductor materials, which is expected to enhance the development of high-performance thermal materials [19]

Policy Developments - The National Medical Products Administration (NMPA) has announced the implementation of the "Quality Management Standards for Online Sales of Medical Devices," effective from October 1, 2025. Regulatory authorities are required to guide online sellers and e-commerce platforms in conducting internal training and assessments related to quality management systems, product information display, and risk monitoring [2]. Drug and Device Approvals - BeiGene announced positive results from the Phase 2 clinical trial (DeLLphi-307) of tarlatamab for treating extensive-stage small cell lung cancer (ES-SCLC) patients in China, with detailed data to be presented at an upcoming medical conference [4]. Capital Market Activities - Shanghai BoYin Biotechnology Co., Ltd. has completed a multi-million angel round financing, led by Zhangjiang Life and Health Industry Incubation Angel Fund, with funds aimed at advancing the company's product pipeline and early clinical validation of its first product [7]. Industry Developments - Yuheng Pharmaceutical has signed a co-promotion agreement with Xinghe Pharmaceutical for Pemafibrate, a novel selective PPARα modulator, which will take effect on June 1, 2025. This agreement is expected to enhance Yuheng's product pipeline and potential profit growth, although it will face competition from established products [9]. Shareholder Activities - Chengdu XianDao announced that shareholder Anji Dongfang Jiayu Enterprise Management Partnership reduced its stake by 1 million shares, decreasing its ownership from 6.2% to 5.95% [12]. - BioVeda China RMB Investment Limited plans to reduce its stake in AoJing Medical by up to 135,550 shares, having already reduced its holdings by 34,510 shares, representing 0.25% of the total shares [13].

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-053 哈尔滨誉衡药业股份有限公司 关于与兴和制药（中国）有限公司就佩玛贝特片签订共同推广协议 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、协议签署时间及主要内容 （一）协议签署时间 2025 年 5 月 23 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）与 兴和制药（中国）有限公司（以下简称"兴和制药"）就"佩玛贝特片"（商品 名：派龙达）签订《共同推广协议》（以下简称"协议"）。 协议将于 2025 年 6 月 1 日生效。 （二）协议主要内容 1、兴和制药授予公司在协议约定区域内推广佩玛贝特片（商品名：派龙达）。 2、公司负责在协议约定区域内推广佩玛贝特片（商品名：派龙达）并履行 协议项下的相关义务。 3、兴和制药将按照协议约定向公司支付服务费及推广支持费。 4、协议初始期限为 2025 年 6 月 1 日至 2027 年 12 月 31 日。如果任何一方 在初始期限结束前六个月未向另一方告知其终止协议的意向，则协议期限将在初 始期限结束后自 ...

Core Viewpoint - The announcement highlights a collaboration between Yuheng Pharmaceutical and Xinghe Pharmaceutical for the promotion of Pemabate Tablets, which is expected to enhance Yuheng's product line and competitiveness in the cardiovascular field [1]. Group 1 - Yuheng Pharmaceutical signed a co-promotion agreement with Xinghe Pharmaceutical on May 23, 2025, for Pemabate Tablets [1]. - The agreement will take effect on June 1, 2025, with an initial term until December 31, 2027, and it can be automatically renewed thereafter [1]. - Xinghe Pharmaceutical authorizes Yuheng Pharmaceutical to promote Pemabate Tablets in designated areas and will pay service and promotional support fees [1]. Group 2 - Pemabate Tablets are the world's first novel high-selectivity PPARα modulator, primarily used to lower triglyceride levels in adult patients with non-familial hypertriglyceridemia [1]. - This collaboration is expected to enrich Yuheng Pharmaceutical's product portfolio and strengthen its competitive position in the cardiovascular sector [1].

Group 1 - The hepatitis concept sector rose by 0.89%, ranking 9th among concept sectors, with 85 stocks increasing in value [1] - Key performers included Haichen Pharmaceutical, which hit a 20% limit up, along with Zhongsheng Pharmaceutical and Haixiang Pharmaceutical also reaching their limit up [1] - Notable gainers included Yangguang Nuohe, Kaipu Biological, and Yuheng Pharmaceutical, with increases of 12.55%, 8.80%, and 5.51% respectively [1] Group 2 - The hepatitis concept sector saw a net inflow of 596 million yuan from main funds, with 57 stocks receiving net inflows [2] - Haichen Pharmaceutical led the net inflow with 179 million yuan, followed closely by Zhongsheng Pharmaceutical and Yuheng Pharmaceutical with 177 million yuan and 155 million yuan respectively [2] - The net inflow ratios for Zhongsheng Pharmaceutical, Haichen Pharmaceutical, and Yuheng Pharmaceutical were 42.93%, 15.92%, and 14.73% respectively [3] Group 3 - The overall market performance showed a mixed trend, with some sectors like controllable nuclear fusion and CRO concepts gaining while military equipment restructuring and other sectors faced declines [2] - The hepatitis concept sector's performance was bolstered by significant capital inflows, indicating strong investor interest [2][3] - The trading volume and turnover rates for leading stocks in the hepatitis sector were notably high, reflecting active trading and investor engagement [3][4]